

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Nontargeted Therapy for Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. In the Phase III KEYNOTE-024 trial, pembrolizumab monotherapy demonstrated benefit for patients with previously untreated metastatic non-small cell lung cancer and which levels of PD-L1 expression?**

 - Low levels of PD-L1 expression only
 - High levels of PD-L1 expression only
 - Low or high levels of PD-L1 expression
- 2. On the basis of results from the Phase III CheckMate 743 trial, the FDA approved the combination of ipilimumab and nivolumab for patients with unresectable malignant pleural mesothelioma in which of the following settings?**

 - As first-line treatment
 - As second-line treatment
 - As late-line treatment
- 3. Which of the following statements is true about the management of newly diagnosed extensive-stage small cell lung cancer (SCLC)?**

 - The combination of chemotherapy and an immune checkpoint inhibitor has become the standard approach
 - Immune checkpoint inhibitors are not currently used as first-line therapy
- 4. What is the mechanism of action of lurbinectedin, approved by the FDA for patients with metastatic SCLC who experience disease progression on or after a platinum-based chemotherapy regimen?**

 - It inhibits transcription and effects immune responses
 - It inhibits tyrosine kinases
 - It inhibits PD-1